Harmony Biosciences Holdings, Inc. · NASDAQ:HRMY
Harmony Biosciences — Q1 2022 Earnings Presentation
12 slides from Harmony Biosciences's earnings presentation, May 3, 2022
Slide 1: Harmony Biosciences Q1 2022 Financial and Business Update
Harmony Biosciences Q1 2022 Financial and Business Update May 3, 2022
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation includes forward‐looking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, Inc
Slide 3: Harmony's Strategy for Growth
Harmony’s Strategy for Growth Expand Optimize Acquire Clinical WAKIX ® New Utility of Performance Assets WAKIX 3
Slide 4: Q1 2022 WAKIX Net Revenue Performance
Q1 2022 WAKIX® Net Revenue Performance Q1 2022 Net Revenue of $85.3M 43% ∆ 1Q22 ∆ 1Q22 1Q21 4Q21 1Q22 $85.3 vs. 4Q21 vs. 1Q21 $59.7 $91.2 $85.3 (6%) 43% $59.7 ▪ 43% growth Q1 2022 vs. Q1 2021 ▪ Surpassed $500M in cumulative net revenue – achieved in less than 2 ½ years since launch Q1 2021 Q1 2022 W
Slide 5: Driving Growth Through Our Launch For WAKIX
Driving Growth Through Our Launch For WAKIX Q1 2022 Performance >70% In-Person Access to HCPs Average # of ~3,900 WAKIX Patients Patient Outreach Programs & Support Continued Growth in Depth & Breadth of Prescriber Base Healthcare Professional Educational Initiatives Managed Care >80% U.S. Covered L
Slide 6: INTUNE Study: Registrational Trial of Pitolisant in Idiopathic Hypersomnia
INTUNE Study: Phase 3 Registrational Trial of Pitolisant in Idiopathic Hypersomnia Open-Label Phase (N=~200) Double-Blind Randomized Withdrawal Phase Randomized Responders Screening Pitolisant Titration + Stable Safety + Dose Optimization Dose Placebo Follow-up Baseline Titration: Weeks 1-3 Weeks 7-
Slide 7: Harmony Development Pipeline
Harmony Development Pipeline Regulatory Marketed Upcoming Product / Indication Pre-IND Phase 1 Phase 2 Phase 3 Filing(1) Product Milestones WAKIX® EDS in Narcolepsy (Adults) Cataplexy in Narcolepsy (Adults) Pitolisant Pediatric Trial completed Narcolepsy(2) Idiopathic Trial initiated Hypersomnia (IH
Slide 8: HBS-102: Preclinical POC Study in PWS
HBS-102: Preclinical POC Study in PWS ▪ Melanin Concentrating Hormone (MCH) neurons are located in the hypothalamus and function as a key control center of feeding behavior and energy metabolism ▪ HBS-102 is an MCH receptor-1 (MCHR1) antagonist and this class of compounds has been shown to mediate t
Slide 9: Q1 2022 Financial Highlights
Q1 2022 Financial Highlights (In millions, USD) Net Product Revenues Non-GAAP Adjusted Net Income(1) 43% $85.3 $59.7 94% $31.1 $16.0 Q1 2021 Q1 2022 Q1 2021 Q1 2022 Strong Operating Performance Growth in Net Product Revenues and Non-GAAP Adjusted Net Income(1) 1. Non-GAAP Adjusted Net Income= GAAP N
Slide 10: Q1 2022 Financial Summary
Q1 2022 Financial Summary (In millions, USD) Three Months Ended March 31, 2022 2021 Net Product Revenues $85.3 $59.7 Cost of Product Sold 14.7 10.4 Total Operating Expenses $43.0 $34.7 R&D Expense 7.6 4.7 S&M Expense 17.6 15.5 G&A Expense 17.9 14.5 Net Income $21.5 $7.4 Cash & cash equivalents $224.
Slide 11: Q1 2022 GAAP vs Non-GAAP Reconciliation
Q1 2022 GAAP vs Non-GAAP Reconciliation (In millions, USD) Three Months Ended March 31, 2022 2021 GAAP net income $21.5 $7.4 Non-cash interest expense(1) 0.4 0.7 Depreciation 0.1 0.1 Amortization(2) 5.1 4.6 Stock-based compensation expense 4.9 3.3 Income tax effect related to Non-GAAP adjustments(3)
Slide 12: Thank You
HARMONY BIOSCIENCES Thank You
Harmony Biosciences Holdings — Q1 2022 Earnings Presentation on 6ix